Edition:
United States

Cryoport Inc (CYRX.OQ)

CYRX.OQ on NASDAQ Stock Exchange Capital Market

13.05USD
17 Aug 2018
Change (% chg)

$0.63 (+5.07%)
Prev Close
$12.42
Open
$12.37
Day's High
$13.05
Day's Low
$12.03
Volume
117,794
Avg. Vol
123,370
52-wk High
$16.88
52-wk Low
$6.02

Latest Key Developments (Source: Significant Developments)

Cryoport Reports Q2 Loss Per Share Of $0.09
Thursday, 9 Aug 2018 04:10pm EDT 

Aug 9 (Reuters) - Cryoport Inc ::CRYOPORT REVENUE GROWS 59 PCT FOR SECOND QUARTER 2018; 73 PCT IN BIOPHARMA.Q2 REVENUE $4.6 MILLION VERSUS I/B/E/S VIEW $4.3 MILLION.QTRLY LOSS PER SHARE $0.09.CO HAS NO DEBT, REPORTED $20.0 MILLION IN CASH AND CASH EQUIVALENTS AS OF JUNE 30.  Full Article

Cryoport Qtrly ‍​loss Per Share $0.09
Tuesday, 6 Mar 2018 04:10pm EST 

March 6 (Reuters) - Cryoport Inc ::CRYOPORT REPORTS 56% REVENUE GROWTH FOR FISCAL YEAR ENDED DECEMBER 31, 2017.Q4 REVENUE ROSE 49 PERCENT TO $3.3 MILLION.QTRLY ‍​LOSS PER SHARE $0.09.  Full Article

Cryoport revenue up 52 percent driven by BioPharma
Thursday, 2 Nov 2017 04:10pm EDT 

Nov 2 (Reuters) - Cryoport Inc ::Revenue increased 52 percent to $3.0 million for three month period ended September 30, 2017​.Cryoport Inc - ‍GAAP net loss attributable to common stockholders for three month period ended September 30, 2017 was $0.08 per share​.  Full Article

Cryoport to support commercial launch of Kite Pharma's CAR-T therapy, axi-cel​
Tuesday, 5 Sep 2017 08:30am EDT 

Sept 5 (Reuters) - Cryoport Inc :Cryoport Inc - ‍Cryoport selected to support potential commercial launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel​.Cryoport Inc - ‍will provide logistics support throughout United States in accordance with Kite's plans for patient adoption of axi-cel​.  Full Article

Cryoport reports Q2 loss per share $0.08
Tuesday, 8 Aug 2017 04:10pm EDT 

Aug 9 (Reuters) - Cryoport Inc -:Cryoport revenue up 52% for the second quarter of 2017, driven by biopharma.Q2 revenue $2.9 million versus I/B/E/S view $2.8 million.Q2 gaap loss per share $0.08.  Full Article

Cryoport says Novartis signed agreement contracting co over an initial three-year term for cryogenic logistics support
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Cryoport Inc :Cryoport - Novartis signed agreement contracting co over an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy.  Full Article

Cryoport expands agreement with Sanaria to support grant awards with U.S. National institutes of Health, U.S. army
Wednesday, 7 Jun 2017 08:30am EDT 

June 7 (Reuters) - Cryoport Inc ::Cryoport expands agreement with Sanaria to support grant awards with u.s. National institutes of health and u.s. Army.Cryoport inc - will assist Sanaria Inc in design and implementation of cryogenic cold chain for Sanaria's investigational malaria vaccines.Cryoport Inc - work will assist in implementation in support of anticipated commercial launch of PFSPZ vaccine, which is cryopreserved.Cryoport Inc - work is supported by grants to sanaria from national institute of allergy and infectious diseases, u.s. Department of defense.  Full Article

Cryoport Q1 GAAP loss per share $0.10
Thursday, 4 May 2017 04:10pm EDT 

May 4 (Reuters) - Cryoport Inc ::Cryoport revenue grows by 74%, driven by Biopharma.Q1 GAAP loss per share $0.10.Q1 revenue rose 74 percent to $2.7 million.  Full Article

Cryoport announces pricing of public offering of common stock
Tuesday, 28 Mar 2017 09:30am EDT 

Cryoport Inc : Cryoport announces pricing of public offering of common stock .Cryoport - pricing of its underwritten public offering of an aggregate of 5.5 million newly issued shares of common stock at a price of $2.00 per share.  Full Article

Cryoport announces proposed public offering of common stock
Monday, 27 Mar 2017 04:12pm EDT 

Cryoport Inc - : Cryoport announces proposed public offering of common stock .Expects to use net proceeds from offering of shares for business growth, including as working capital.  Full Article

BRIEF-Cryoport Revenue Grows 48 Pct For First Quarter

* CRYOPORT REVENUE GROWS 48% FOR FIRST QUARTER; 62% IN BIOPHARMA